Overview
- Injectable GLP-1 drugs will be available for about $350 per month via direct purchase initially, with targets to drop to roughly $250 within two years.
- Low-dose oral GLP-1 pills are slated to cost $149 per month if the FDA grants approval.
- Medicare will broaden access next year with a $50 monthly copay for eligible beneficiaries, with officials estimating about 10% could qualify and key pricing changes beginning mid-2026.
- TrumpRx, a federal direct-sales channel, is planned for early 2026 to let consumers buy certain manufacturer-priced medicines at the negotiated rates.
- Eli Lilly and Novo Nordisk receive tariff exemptions and expedited reviews under the agreements, while lower prices for state Medicaid programs will proceed through state-by-state negotiations.